TransMedics (TMDX) director exercises 19,285 options and sells shares

Rhea-AI Filing Summary

TransMedics Group director Thomas J. Gunderson exercised stock options and sold shares in a related move. He exercised options for 19,285 shares of common stock at an exercise price of $2.21 per share and sold 9,624 shares at $75.06 per share to cover the exercise price and tax withholding obligations. After these transactions, he directly held 26,266 shares of TransMedics common stock. The options exercised were granted on August 1, 2016 and are fully vested, and no related derivative position remains from this grant.

Insights

Equity compensation and insider-trading analyst

Routine option exercise with partial sale mainly to cover costs.

Director Thomas J. Gunderson exercised stock options for 19,285 TransMedics shares at $2.21 and sold 9,624 shares at $75.06. Footnotes state the sale was used to cover the option exercise price and related tax withholding obligations.

This pattern is typical of equity compensation events, where insiders monetize a portion of newly acquired shares to handle cash costs rather than making a discretionary portfolio decision. Following the transactions, Gunderson holds 26,266 shares directly, indicating a net increase in his equity exposure from this grant.

Insider Trade Summary

Net Seller: 9,624 shares ($722,377)

Net Sell 3 txns

Insider Gunderson Thomas J.

Role null

Sold 9,624 shs ($722K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	19,285	$0.00	--
Exercise	Common Stock	19,285	$2.21	$43K
Sale	Common Stock	9,624	$75.06	$722K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 26,266 shares (Direct, null)

Footnotes (1)

1. The shares were sold to cover the exercise price and applicable tax withholding obligations in connection with the exercise of the stock options. The stock options were granted on August 1, 2016 and are fully vested.

Key Figures

Shares sold: 9,624 shares Sale price: $75.06 per share Options exercised: 19,285 shares +3 more

6 metrics

Shares sold 9,624 shares Common stock sold at $75.06 per share on June 15, 2026

Sale price $75.06 per share Price for 9,624 TransMedics common shares sold

Options exercised 19,285 shares Common stock acquired via stock option exercise

Exercise price $2.21 per share Stock option (right to buy) exercise price

Shares held after 26,266 shares Direct TransMedics common stock ownership after transactions

Option expiration August 1, 2026 Original expiration date of exercised stock options

Key Terms

open-market sale, Stock Option (Right to Buy), tax withholding obligations, fully vested

4 terms

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

tax withholding obligations financial

"sold to cover the exercise price and applicable tax withholding obligations"

fully vested financial

"The stock options were granted on August 1, 2016 and are fully vested."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gunderson Thomas J.

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MASSACHUSETTS 01810

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		M		19,285	A	$2.21	26,266	D
Common Stock	06/15/2026		S(1)		9,624	D	$75.06	16,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.21	06/15/2026		M			19,285	(2)	08/01/2026	Common Stock	19,285	$0.00	0	D

Explanation of Responses:

1. The shares were sold to cover the exercise price and applicable tax withholding obligations in connection with the exercise of the stock options.

2. The stock options were granted on August 1, 2016 and are fully vested.

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did TransMedics (TMDX) director Thomas J. Gunderson report?

He reported exercising stock options for 19,285 TransMedics common shares at $2.21 per share and selling 9,624 shares at $75.06 per share. These actions were part of a single compensation-related event on June 15, 2026 involving option exercise and a related share sale.

How many TransMedics (TMDX) shares does Thomas J. Gunderson hold after this Form 4?

After the reported transactions, Thomas J. Gunderson directly holds 26,266 shares of TransMedics common stock. This reflects the net position following his exercise of 19,285 stock options and the sale of 9,624 shares to handle exercise and tax obligations.

At what prices did the TransMedics (TMDX) director exercise options and sell shares?

He exercised stock options at an exercise price of $2.21 per share and sold common shares at $75.06 per share. These prices show the option grant’s low strike price relative to the prevailing market sale price on June 15, 2026.

Why did Thomas J. Gunderson sell TransMedics (TMDX) shares in this filing?

According to the footnote, the 9,624 shares were sold to cover the stock option exercise price and applicable tax withholding obligations. This indicates a mechanistic sale tied to compensation, rather than a purely discretionary reduction of his TransMedics shareholdings.

What were the terms of the TransMedics (TMDX) stock options exercised by the director?

The stock options exercised covered 19,285 underlying shares of common stock at a $2.21 exercise price and were fully vested. They were originally granted on August 1, 2016 and carried an expiration date of August 1, 2026 before being fully exercised in this transaction.